In contrast, anti-IL-17A antibodies or IL-17A gene KO resulted in greater resistance to cisplatin-induced nephrotoxicity, confirming IL-17A’s critical role in cisplatin-induced AKI and indicating that antagonizing IL-17A offers substantial protective effects against this condition [83]. The gene discussed is IL17A; the disease is acute kidney injury.